Amyloid β-induced nerve growth factor dysmetabolism in Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 8, 2009, Pages 857-869

  Bruno, Martin A ^a   Leon, Wanda C ^a   Fragoso, Gabriela ^a   Mushynski, Walter E ^a   Almazan, Guillermina ^a   Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

amyloid oligomers; Alzheimer disease; Minocycline; Nerve growth factor; Peroxynitrite; Pro NGF

Indexed keywords

AMYLOID BETA PROTEIN; CD40 ANTIGEN; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MINOCYCLINE; NERVE GROWTH FACTOR; OLIGOMER; PEROXYNITRITE; PLACEBO; 3 NITROTYROSINE; 3-NITROTYROSINE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; DRUG DERIVATIVE; PEPTIDE FRAGMENT; PEROXYNITROUS ACID; PRO NERVE GROWTH FACTOR, RAT; PRO-NERVE GROWTH FACTOR, RAT; PROTEIN PRECURSOR; TYROSINE;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COGNITION; CONTROLLED STUDY; FEMALE; FOREBRAIN; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; METABOLISM; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECT; FISCHER 344 RAT; GENETICS; IMMUNOPRECIPITATION; MAZE TEST; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REACTION TIME; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD40; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MATRIX METALLOPROTEINASE 9; MAZE LEARNING; MICE; MICE, TRANSGENIC; MINOCYCLINE; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; PEROXYNITROUS ACID; PROTEIN PRECURSORS; RATS; RATS, INBRED F344; REACTION TIME; TYROSINE; UP-REGULATION;

EID: 69449097269     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181aed9e6     Document Type: Article

References (58)

1. Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer's 2007;12:37-52
2. Cuello AC. Effects of trophic factors on the CNS cholinergic phenotype. Prog Brain Res 1996;109:347-358
3. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995;270: 593-598
4. Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci U S A 1999;96:4067-4072
5. Fahnestock M, Scott SA, Jette N, et al. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res Mol Brain Res 1996;42:175-178
6. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res 1994;25:242-250
7. Fahnestock M, Michalski B, Xu B, et al. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001;18:210-220
8. Peng S, Wuu J, Mufson EJ, et al. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 2004;63:641-649
9. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005;93:1412-1421
10. Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 2005;64:263-272
11. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 2006; 103:6735-6740
12. Lee CZ, Yao JS, Huang Y, et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006;26:1157-1164
13. Venero JL, Hefti F, Knusel B. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: Comparison between intraparenchymal and intraventricular administration. Mol Pharmacol 1996; 49:303-310
14. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 2004; 56:675-688
15. Demuro A, Mina E, Kayed R, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005;280:17294-17300
16. Pehar M, Vargas MR, Robinson KM, et al. Peroxynitrite transforms nerve growth factor into an apoptotic factor for motor neurons. Free Radic Biol Med 2006;41:1632-1644
17. Lee R, Kermani P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science 2001;294:1945-1948
18. Backstrom JR, Miller CA, Tokes ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: Identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992;58:983-992
19. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003;43:191-196
20. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. Science 2002;297:1186-1190
21. Walker DG, Link J, Lue LF, et al. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006;79: 596-610
22. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218
23. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-121
24. Luth HJ, Holzer M, Gartner U, et al. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: Evidence for an induction by amyloid pathology. Brain Res 2001;913:57-67
25. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002;953:135-143
26. Nguyen VT, Walker WS, Benveniste EN. Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur J Immunol 1998;28:2537-2548
27. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286:2352-2355
28. Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 2002;23:31-39
29. Togo T, Akiyama H, Kondo H, et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res 2000; 885:117-121
30. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862
31. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866
32. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577
33. Walsh DM, Selkoe DJ. A beta oligomersVA decade of discovery. J Neurochem 2007;101:1172-1184
34. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489
35. Familian A, Eikelenboom P, Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci Lett 2007;416:87-91
36. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93:14014-14019
37. Ryu JK, Franciosi S, Sattayaprasert P, et al. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 2004;48:85-90
38. Hensley K, Maidt ML, Yu Z, et al. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates regionspecific accumulation. J Neurosci 1998;18:8126-8132
39. Smith MA, Richey Harris PL, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657
40. Bruno MA, Clarke PB, Seltzer A, et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci 2004;24: 8009-8018
41. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84
42. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357
43. Stepanichev MY, Moiseeva YV, Lazareva NA, et al. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 2003;61:197-205
44. Olariu A, Tran MH, Yamada K, et al. Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 2001;108:1065-1079
45. Tran MH, Yamada K, Olariu A, et al. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: Association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 2001;15:1407-1409
46. Castegna A, Thongboonkerd V, Klein JB, et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85: 1394-1401
47. Torreilles F, Salman-Tabcheh S, Guerin M, et al. Neurodegenerative disorders: The role of peroxynitrite. Brain Res Brain Res Rev 1999;30: 153-163
48. Xie Z, Wei M, Morgan TE, et al. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci 2002;22:3484-3492
49. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 2005;7:1223-1233
50. Li J, Baud O, Vartanian T, et al. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci U S A 2005;102: 9936-9941
51. Wang Q, Rowan MJ, Anwyl R. Beta-amyloidYmediated inhibition of NMDA receptorYdependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004;24:6049-6056
52. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003;25:295-311
53. Heneka MT, Feinstein DL. Expression and function of inducible nitric oxide synthase in neurons. J Neuroimmunol 2001;114:8-18
54. Domeniconi M, Hempstead BL, Chao MV. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol Cell Neurosci 2007; 34:271-279
55. Volosin M, Song W, Almeida RD, et al. Interaction of survival and death signaling in basal forebrain neurons: Roles of neurotrophins and proneurotrophins. J Neurosci 2006;26:7756-7766
56. Figueiredo BC, Skup M, Bedard AM, et al. Differential expression of p140trk, p75NGFR and growth-associated phosphoprotein-43 genes in nucleus basalis magnocellularis, thalamus and adjacent cortex following neocortical infarction and nerve growth factor treatment. Neuroscience 1995;68:29-45
57. Holtzman DM, Li Y, Parada LF, et al. p140trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF. Neuron 1992;9:465-478
58. Li Y, Holtzman DM, Kromer LF, et al. Regulation of TrkA and ChAT expression in developing rat basal forebrain: Evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci 1995;15:2888-905